GeneDx Holdings (WGS) is back in focus after publishing new data in Genetics in Medicine on hospital wide rapid genome sequencing in pediatric inpatient care, which is drawing fresh attention to the stock.

The latest study appears to have arrived alongside a sharp upswing in GeneDx Holdings' recent momentum, with a 30 day share price return of 47.89% and a 90 day share price return of 81.30%. However, the year to date share price return is still down 33.93% and the 1 year total shareholder return is down 30.77%, following a very large 3 year total shareholder return that is more than 18x.

If this kind of healthcare AI progress has your attention, it could be worth seeing what else is moving by checking out 42 healthcare AI stocks

After a 30 day jump and a strong 3 year run that is more than 18x, the key issue for GeneDx Holdings now is simple. Is most of the rerating already behind the stock, or is there still meaningful upside ahead, as the valuation section shows?

Most Popular Narrative: 13.5% Overvalued

Compared with the last close of $87.41, the most followed narrative sets a fair value of $77.00 for GeneDx Holdings and builds a detailed case around future growth and profitability assumptions.

Rapid expansion into new and underpenetrated markets, including general pediatrics, NICU, and additional pediatric specialties, positions GeneDx for substantial future volume and revenue growth as adoption of genomics as a frontline diagnostic tool accelerates. Scaling proprietary AI powered genomic interpretation platforms and integrating newly acquired Fabric Genomics technology improves efficiency and accuracy, which should both lower per sample costs and support margin expansion as the business grows.

Curious what sits behind that growth story? The narrative leans on ambitious revenue expansion, margin improvement and a premium future earnings multiple. Want to see which specific forecasts need to land for $77.00 to make sense?

Result: Fair Value of $77.00 (OVERVALUED)

However, there are still clear risks to that GeneDx Holdings narrative, including reimbursement pressure and slower adoption in pediatrics, which could challenge those growth assumptions.

Another View on GeneDx Holdings: Cash Flow Versus Narratives

The most popular narrative around GeneDx Holdings points to a fair value of $77.00 and frames the stock as about 13.5% overvalued at around $87.41. A different lens tells another story. The SWS DCF model estimates a future cash flow value of $236.93, which implies the shares trade at a 63.1% discount to that figure.

This kind of gap between a sentiment driven narrative and a cash flow based model can signal either a margin of safety or a sign that the model assumptions are too generous. Which side of that tradeoff do you think fits GeneDx Holdings best over the next few years.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out GeneDx Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mixed signals in the GeneDx Holdings story so far, it makes sense to zoom in on the raw data and decide quickly what matters most for you. To see what investors are optimistic about, review the 2 key rewards.

Looking for more investment ideas beyond GeneDx Holdings?

If GeneDx Holdings has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas built from clear financial filters and transparent data.

• Target potential mispricing by scanning companies that look attractively priced relative to quality using the 49 high quality undervalued stocks.
• Lock in income focused ideas by reviewing stocks that feature higher yields in the 12 dividend fortresses.
• Filter for resilience by checking companies with stronger balance sheets and fundamentals through the solid balance sheet and fundamentals stocks screener (51 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.